| Literature DB >> 35742510 |
Muhammad Shahzad Chohan1, Mahesh Attimarad2, Katharigatta Narayanaswamy Venugopala2,3, Anroop Balachandran Nair2, Nagaraja Sreeharsha2,4, Efren Ii Plaza Molina5, Ramling Bhagavantrao Kotnal6, Sheeba Shafi7, Marysheela David7, Pottathil Shinu1, Abdulrahman Ibrahim Altaysan2, Abdulmalek Ahmed Balgoname2.
Abstract
The development of an environmentally friendly analytical technique for simultaneous measurement of medicines with large concentration differences is difficult yet critical for environmental protection. Hence, in this work, new manipulated UV-spectroscopic methods with high scaling factors were established for concurrent quantification of telmisartan (TEL) and benidipine (BEN) in fixed-dose combinations. Two different methods were developed and established by calculation of peak height at zero crossing point of second derivative and the ratio of first derivative spectra with a scaling factor of 200 and 100, respectively. The absorption difference between the peaks and troughs of the ratio spectra, as well as continuous subtraction from ratio spectra, were established as additional methods. In addition, new procedures were validated using ICH recommendations. The proposed methods' linearity curves were constructed in the range of 0.5-10 µg mL-1 and 1-30 µg mL-1 for BEN and TEL, respectively, under optimized conditions. Furthermore, both the detection (0.088-0.139 µg mL-1 for BEN and 0.256-0.288 µg mL-1 for TEL) and quantification limits (0.293-0.465 µg mL-1 for BEN and 0.801-0.962 µg mL-1 for TEL) were adequate for quantifying both analytes in the formulation ratios. The accuracy and precision were confirmed by the good recovery percent (98.37%-100.6%), with low percent relative error (0.67%-1.70%) and less than 2 percent relative standard deviation, respectively. The specificity of the methods was proven by accurate and precise outcomes from the standard addition method and analysis of laboratory mixed solutions with large differences in concentrations of both analytes. Finally, the BEN and TEL content of the formulations was determined simultaneously without prior separation using these first ever reported spectroscopic methods. Furthermore, developed UV derivative spectroscopic methods demonstrated high greenness and whiteness when compared to the reported HPLC methods. These findings show that the projected methods were effective, practical, and environmentally acceptable for quality control of BEN and TEL in multicomponent formulations.Entities:
Keywords: benidipine; formulation; quantification; ratio derivative spectroscopy; scaling factor; telmisartan; validation
Mesh:
Substances:
Year: 2022 PMID: 35742510 PMCID: PMC9223904 DOI: 10.3390/ijerph19127260
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Chemical structure of benidipine (A) and telmisartan (B).
Figure 2Zero-order UV absorption spectra of BEN (Red), TEL (Blue), and mixture (Black) (A). Second-order derivative spectra of BEN (Red), TEL (Blue), and mixture (Black) (B). Second-order derivative spectra of BEN (0.5–10 µg mL−1) (C). Second-order derivative spectra of TEL (1–24 µg mL−1) (D).
Figure 3Ratio absorption spectra of BEN (A). Ratio absorption of BEN pure (Red) and mixture (Blue) (B). Ratio absorption spectra of TEL (C). Ratio absorption of TEL pure (Red) and mixture (Blue) (D). Arrow position indicates the wavelength at which constant was subtracted.
Figure 4Ratio first derivative spectra of BEN (0.5–10 µg mL−1) (A). Ratio first derivative spectra of TEL (1–30 µg mL−1) (B). Comparison of ratio first derivative spectra of pure (Red) BEN (C) and TEL (D) with the mixture (Blue).
Figure 5Zero-order spectra of BEN (0.5–10 µg mL−1) (A). Zero-order spectra of TEL (1–30 µg mL−1) (B). Comparison of zero-order spectra of pure (Red) BEN (C) and TEL (D) with the mixture (Blue).
Validation parameter results of the proposed spectroscopic methods for the simultaneous determination of BEN and TEL.
| Validation | Benidipine | Telmisartan | ||||||
|---|---|---|---|---|---|---|---|---|
| SDM | RAD | RFD | CSM | SDM | RAD | RFD | CSM | |
| Wavelength (nm) | 239.8 | 360.8–304.2 | 344.0 | 238.2 | 233.1 | 305.4–244.5 | 318.6 | 299.5 |
| Linearity range (µg mL−1) | 0.5–10 | 0.5–10 | 0.5–10 | 0.5–10 | 1–24 | 1–30 | 1–30 | 1–30 |
| Slope | 0.0509 | 1.0784 | 4.5038 | 0.0445 | 0.1068 | 1.5785 | 8.3934 | 0.0518 |
| Intercept | −0.0087 | −0.0941 | −0.4644 | −0.0062 | 0.0149 | 0.6598 | 2.6796 | −0.0089 |
| Regression coefficient (r2) | 0.9998 | 0.9998 | 0.9999 | 0.9997 | 0.9998 | 0.9997 | 0.9998 | 0.9995 |
| LOD (µg mL−1) | 0.121 | 0.088 | 0.099 | 0.139 | 0.288 | 0.287 | 0.256 | 0.268 |
| LOQ (µg mL−1) | 0.402 | 0.293 | 0.332 | 0.465 | 0.962 | 0.951 | 0.801 | 0.945 |
| Accuracy | 99.61 ± 1.47 | 99.31 ± 0.94 | 100.62 ± 1.70 | 98.37 ± 1.08 | 99.35 ± 0.89 | 98.44 ± 0.83 | 99.27 ± 1.58 | 100.76 ± 0.67 |
| Precision (%RSD) | ||||||||
| Intraday | 0.864 | 1.247 | 0.679 | 0.758 | 1.471 | 0.947 | 1.622 | 0.765 |
| Interday | 1.408 | 1.353 | 0.964 | 1.796 | 1.592 | 1.203 | 1.493 | 1.531 |
RSE: relative standard error; RSD: relative standard deviation.
Assay results of the laboratory mixed solutions of BEN and TEL.
| Laboratory Prepared Mixture (µg mL−1) | Benidipine (% Recovery) | Telmisartan (% Recovery) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| BEN | TEL | SDM | RAD | RFD | CSM | SDM | RAD | RFD | CSM |
| 1 | 20 | 100.45 | 100.62 | 98.48 | 99.63 | 98.76 | 100.54 | 98.47 | 101.34 |
| 5 | 20 | 99.54 | 98.34 | 99.57 | 100.92 | 99.34 | 99.33 | 99.48 | 98.47 |
| 10 | 10 | 100.57 | 100.86 | 98.37 | 98.83 | 98.81 | 99.07 | 99.62 | 100.62 |
| 0.5 | 5 | 99.06 | 100.92 | 100.65 | 100.75 | 100.83 | 101.73 | 98.24 | 99.54 |
| 2 | 24 | 99.72 | 100.04 | 99.53 | 100.17 | 99.66 | 100.04 | 98.42 | 99.54 |
| Across Mean | 99.87 | 100.16 | 99.32 | 100.06 | 99.48 | 100.14 | 98.85 | 99.90 | |
| Standard Deviation | 0.76 | 0.49 | 1.14 | 0.98 | 1.01 | 1.35 | 0.75 | 0.62 | |
Ruggedness results.
| Analyst | Benidipine (Mean % ± %RSD) | Telmisartan (Mean % ± %RSD) | ||||||
|---|---|---|---|---|---|---|---|---|
| SDM | RAD | RFD | CSM | SDM | RAD | RFD | CSM | |
| Analyst 1 | 99.45 ± 0.95 | 100.78 ± 1.58 | 98.27 ± 0.67 | 99.43 ± 0.72 | 100.12 ± 1.47 | 99.64 ± 1.08 | 98.06 ± 0.47 | 99.11 ± 0.93 |
| Analyst 2 | 99.07 ± 0.94 | 98.59 ± 0.85 | 99.66 ± 0.82 | 100.28 ± 0.95 | 99.53 ± 1.25 | 98.62 ± 1.06 | 99.43 ± 1.72 | 101.04 ± 1.23 |
Assay results of the formulation and the standard addition method results.
| Formulation Concentration | Benidipine (Mean% ± SD) | Telmisartan (Mean% ± SD) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| BEN | TEL | SDM | RAD | RFD | CSM | SDM | RAD | RFD | CSM |
| 4 mg | 40 mg | 98.27 ± 1.34 | 99.07 ± 0.86 | 98.61 ± 1.83 | 98.92 ± 0.95 | 99.82 ± 0.66 | 98.87 ± 0.78 | 99.06 ± 0.80 | 98.92 ± 1.05 |
| 4 mg | 80 mg | 100.14 ± 0.96 | 100.75 ± 1.34 | 98.67 ± 1.06 | 99.55 ± 0.73 | 100.49 ± 1.72 | 99.36 ± 1.49 | 101.05 ± 0.79 | 100.67 ± 1.53 |
| Standard Addition Method | |||||||||
| Amount Added (µg mL−1) | Benidipine (% Recovery) | Telmisartan (% Recovery) | |||||||
| 1 | 4 | 99.54 | 98.34 | 99.57 | 100.92 | 99.34 | 99.33 | 99.48 | 98.47 |
| 2 | 8 | 100.57 | 100.86 | 98.37 | 98.83 | 98.81 | 99.07 | 100.44 | 100.62 |
| 3 | 12 | 99.06 | 100.92 | 100.65 | 100.75 | 100.83 | 101.73 | 100.03 | 99.54 |
| Across Mean | 99.72 | 100.04 | 99.53 | 100.17 | 99.66 | 100.04 | 99.98 | 99.54 | |
| %RSD | 0.77 | 1.47 | 1.15 | 1.16 | 1.05 | 1.47 | 0.48 | 1.08 | |
SD: standard deviation, %RSD: percentage relative standard deviation.
Figure 6AGREE score for UV spectrophotometric method (A) and HPLC methods (B–D). Comparison of whiteness score between UV spectrophotometric method and HPLC methods (E)—HPLC IJSR [32], HPLC WJPPS [33], and HPLC APCR [34].